Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 1
2016 1
2018 1
2021 2
2022 2
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

8 results

Results by year

Filters applied: . Clear all
Page 1
Mitotic perturbation is a key mechanism of action of decitabine in myeloid tumor treatment.
Yabushita T, Chinen T, Nishiyama A, Asada S, Shimura R, Isobe T, Yamamoto K, Sato N, Enomoto Y, Tanaka Y, Fukuyama T, Satoh H, Kato K, Saitoh K, Ishikawa T, Soga T, Nannya Y, Fukagawa T, Nakanishi M, Kitagawa D, Kitamura T, Goyama S. Yabushita T, et al. Among authors: sato n. Cell Rep. 2023 Sep 26;42(9):113098. doi: 10.1016/j.celrep.2023.113098. Epub 2023 Sep 14. Cell Rep. 2023. PMID: 37714156 Free article.
IMPDH inhibition activates TLR-VCAM1 pathway and suppresses the development of MLL-fusion leukemia.
Liu X, Sato N, Yabushita T, Li J, Jia Y, Tamura M, Asada S, Fujino T, Fukushima T, Yonezawa T, Tanaka Y, Fukuyama T, Tsuchiya A, Shikata S, Iwamura H, Kinouchi C, Komatsu K, Yamasaki S, Shibata T, Sasaki AT, Schibler J, Wunderlich M, O'Brien E, Mizukawa B, Mulloy JC, Sugiura Y, Takizawa H, Shibata T, Miyake K, Kitamura T, Goyama S. Liu X, et al. Among authors: sato n. EMBO Mol Med. 2023 Jan 11;15(1):e15631. doi: 10.15252/emmm.202115631. Epub 2022 Dec 1. EMBO Mol Med. 2023. PMID: 36453131 Free PMC article.
CHIP-associated mutant ASXL1 in blood cells promotes solid tumor progression.
Liu X, Sato N, Shimosato Y, Wang TW, Denda T, Chang YH, Yabushita T, Fujino T, Asada S, Tanaka Y, Fukuyama T, Enomoto Y, Ota Y, Sakamoto T, Kitamura T, Goyama S. Liu X, et al. Among authors: sato n. Cancer Sci. 2022 Apr;113(4):1182-1194. doi: 10.1111/cas.15294. Epub 2022 Feb 26. Cancer Sci. 2022. PMID: 35133065 Free PMC article.
Mutant ASXL1 induces age-related expansion of phenotypic hematopoietic stem cells through activation of Akt/mTOR pathway.
Fujino T, Goyama S, Sugiura Y, Inoue D, Asada S, Yamasaki S, Matsumoto A, Yamaguchi K, Isobe Y, Tsuchiya A, Shikata S, Sato N, Morinaga H, Fukuyama T, Tanaka Y, Fukushima T, Takeda R, Yamamoto K, Honda H, Nishimura EK, Furukawa Y, Shibata T, Abdel-Wahab O, Suematsu M, Kitamura T. Fujino T, et al. Among authors: sato n. Nat Commun. 2021 Mar 23;12(1):1826. doi: 10.1038/s41467-021-22053-y. Nat Commun. 2021. PMID: 33758188 Free PMC article.
[Repeated rituximab-induced serum sickness with anaphylaxis].
Isoda A, Ishikawa T, Sato N, Miyazawa Y, Matsumoto M, Sawamura M. Isoda A, et al. Among authors: sato n. Rinsho Ketsueki. 2016 Jun;57(6):771-3. doi: 10.11406/rinketsu.57.771. Rinsho Ketsueki. 2016. PMID: 27384859 Japanese.
A histone modifier, ASXL1, interacts with NONO and is involved in paraspeckle formation in hematopoietic cells.
Yamamoto K, Goyama S, Asada S, Fujino T, Yonezawa T, Sato N, Takeda R, Tsuchiya A, Fukuyama T, Tanaka Y, Yokoyama A, Toya H, Kon A, Nannya Y, Onoguchi-Mizutani R, Nakagawa S, Hirose T, Ogawa S, Akimitsu N, Kitamura T. Yamamoto K, et al. Among authors: sato n. Cell Rep. 2021 Aug 24;36(8):109576. doi: 10.1016/j.celrep.2021.109576. Cell Rep. 2021. PMID: 34433054 Free article.